Antonios Charokopos

Dr. Antonios Charokopos

School of Medicine, University of Cyprus, Nicosia, Lefkosía, Cyprus
+1
orcid
ILD | Bronchoscopy | Exercise Physiology | Sleep

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Acta Biomaterialia
Verified
Journal Article
Closed access
LMLaura Beth Moore
Laura Beth Moore
ASAndrew J. Sawyer
Andrew J. Sawyer
Antonios CharokoposAntonios Charokopos
Antonios Charokopos
ESEleni A. Skokos
Eleni A. Skokos
Themis KyriakidesThemis Kyriakides
Themis Kyriakides

1 November 2021 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
Antonios CharokoposAntonios Charokopos
Antonios Charokopos
SBSidney S. Braman
Sidney S. Braman
SBStacey A. Whittaker Brown
Stacey A. Whittaker Brown
GMGrace Mhango
Grace Mhango
JDJuan P. De-Torres
Juan P. De-Torres
JWJuan P. Wisnivesky
Juan P. Wisnivesky
Rationale: Chronic obstructive pulmonary disease (COPD) is a well-established independent risk factor for lung cancer; however, the literature on the association between asthma and lung cancer is mixed. Whether asthma–COPD overlap (ACO) is associated with lung cancer has not been studied. Objectives: We aimed to compare lung cancer risk among patients with ACO versus COPD and other conditions associated with airway obstruction. Methods: We studied 13,939 smokers from the National Lung Cancer Screening Trial who had baseline spirometry and used spirometric indices and history of childhood asthma to categorize participants into five specific airway disease subgroups. We used Poisson regression to compare unadjusted and adjusted lung cancer risk. Results: The incidence rate of lung cancer per 1,000 person-years was as follows: ACO, 13.2 (95% confidence interval [CI], 8.1–21.5); COPD, 11.7 (95% CI, 10.5–13.1); asthmatic smokers, 1.8 (95% CI, 0.6–5.4); Global Initiative for Chronic Obstructive Lung Disease–Unclassified, 7.7 (95% CI, 6.4–9.2); and normal spirometry smokers, 4.1 (95% CI, 3.5–4.8). Patients with ACO had increased adjusted risk of lung cancer compared with patients with asthma (incidence rate ratio [IRR], 4.5; 95% CI, 1.3–15.8) and normal spirometry smokers (IRR, 2.3; 95% CI, 1.3–4.2) in models adjusting for other risk factors. Adjusted lung cancer incidence in patients with ACO and COPD were not found to be different (IRR, 1.2; 95% CI, 0.7–2.1). Conclusions: The risk of lung cancer among patients with ACO is similar to those with COPD and higher than other groups of smokers. These results provide further evidence that COPD, with or without a history of childhood asthma, is an independent risk factor for lung cancer.

Verified
Journal Article
Open access
PDF file
TMTeng Moua
Teng Moua
TPTananchai Petnak
Tananchai Petnak
Antonios CharokoposAntonios Charokopos
Antonios Charokopos
MBMisbah Baqir
Misbah Baqir
JRJay Ryu
Jay Ryu
Recent advances in fibrotic hypersensitivity pneumonitis include improved diagnostic guidance, systematic assessments of immunosuppressive therapy, and the recent availability of antifibrotic therapy (nintedanib) for those with progressive disease. A standardized approach to diagnosis may lead to better inclusion criteria for future therapeutic protocols and delineation of disease or treatment response predictors for real-world management. This review will highlight current diagnostic and treatment challenges and remaining knowledge gaps or areas of uncertainty, with a practical overview of supporting evidence and its clinical implications. Exposure history, serologic testing for antigen sensitivity, bronchoalveolar lavage lymphocytosis, histopathology, and radiologic findings will be covered in the diagnosis section, with immunosuppression, antifibrotic therapy, lung transplantation, and disease prognosis in the treatment and management section.

22 May 2023 in Medicina
Verified
Journal Article
Open access
PDF file
Igor DumicIgor Dumic
Igor Dumic
Antonios CharokoposAntonios Charokopos
Antonios Charokopos
APAngadbir Singh Parmar
Angadbir Singh Parmar
CGChristopher Grant
Christopher Grant
RCRonin Joshua So Cosiquien
Ronin Joshua So Cosiquien
EPEmilia Petcu
Emilia Petcu
Nintedanib is a tyrosine kinase inhibitor that was approved for the treatment of patients with idiopathic pulmonary fibrosis in 2014. The most common side effect of Nintedanib is diarrhea, and thrombocytopenia is a rare side effect of Nintedanib. The exact mechanism is unknown, and the literature lacks case reports of this phenomenon. Here, we report the case of a patient who developed thrombocytopenia 12 weeks after starting treatment with Nintedanib. The patient underwent an extensive work up for infectious, hematological, autoimmune, and neoplastic diseases. The patient’s thrombocytopenia resolved following cessation of Nintedanib. This case is significant as it reports a rare side effect that might have detrimental consequences if not recognized and treated timely. Additionally, the onset of thrombocytopenia was delayed, 3 months after the initiation of Nintedanib. We also highlight the various literature regarding drug-induced thrombocytopenia and explore the necessary work-up needed to exclude other potential diagnoses. We hope to advocate for multidisciplinary teams to be aware of patients with pulmonary fibrosis on Nintedanib so that this adverse effect can be recognized promptly.

15 May 2019 in Journal of Clinical Sleep Medicine
Verified
Journal Article
Closed access
Antonios CharokoposAntonios Charokopos
Antonios Charokopos
MCMary Elizabeth Card
Mary Elizabeth Card
RMRichard Peter Manes
Richard Peter Manes
ASAlbert Shaw
Albert Shaw
Pneumocephalus, or air within the cranium, can be caused by trauma, intracranial infections, or tumors, and can also occur as a complication of neurosurgery and lumbar puncture. Continuous positive...

9 January 2023 in World Journal of Critical Care Medicine
Verified
Journal Article
Open access
MLMaulik K Lathiya
Maulik K Lathiya
EPEmily Pepperl
Emily Pepperl
DSDaniel Schaefer
Daniel Schaefer
HAHussam Al-Sharif
Hussam Al-Sharif
AZAdel Zurob
Adel Zurob
Antonios CharokoposAntonios Charokopos
Antonios Charokopos
Vasopressin-induced hyponatremia in an adult normotensive trauma patient: A case report